ARCHIVES

In Brief: Oldham To Head Biological Response Modifiers Program; Walter, Namovicz Named Acting Heads

This article is from The Cancer Letter archive.

Vol. 06 No. 32 | August 8, 1980

Download PDF Visit The Full Archive

Related Articles

“Bring Contracts Under Control, Save $100,00 A Year,” Samuels Tells NCI

November 2, 1979

In Brief: Gene Therapy Pioneer Michael Blaese To Leave NIH For Biotechnology Firm

January 16, 1998

Multivitamin Use Doesn’t Impact Outcomes, Study Finds

September 24, 2010

Cancer Center Directors to Develop Blueprint for Progress That’s “Honest,” M.D. Anderson’s John Mendelsohn Says.

November 22, 2006

Clinical Trials Approved By NCI CTEP Last Month

February 25, 2011

Campus-Dweller Rabson Finds Comfort In NIH Security.

December 14, 2001